News | November 07, 2023
Sun Pharma Advanced Research posts Q2 FY24 loss at Rs. 86.42 Cr
Sun Pharma Advanced Research Company Limited has reported total income of Rs. 29.67 crores during the period ended September 30, 2023
Sun Pharma Advanced Research Company Limited has reported total income of Rs. 29.67 crores during the period ended September 30, 2023
Sun Pharmaceutical Industries has reported total income of Rs. 12486.02 crores during the period ended September 30, 2023
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Post-acquisition of the balance 25% outstanding shares will result into Sun Pharma de México, S.A. de C.V. becoming a wholly-owned subsidiary of the company.
WINLEVI works differently from any other topical acne treatment
Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi (Sovateltide)
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
